Detalhe da pesquisa
1.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
N Engl J Med
; 387(5): 421-432, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921451
2.
RNA-binding protein Hermes/RBPMS inversely affects synapse density and axon arbor formation in retinal ganglion cells in vivo.
J Neurosci
; 33(25): 10384-95, 2013 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23785151
3.
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Nat Med
; 30(4): 1096-1103, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622249
4.
Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.
Sci Rep
; 12(1): 12081, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35840753
5.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Front Neurol
; 12: 705407, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34659081
6.
This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists.
J Parkinsons Dis
; 12(8): 2293-2296, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36404558
7.
Mechanosensing is critical for axon growth in the developing brain.
Nat Neurosci
; 19(12): 1592-1598, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27643431
8.
Effects of cyclosporine A and its immunosuppressive or non-immunosuppressive derivatives [D-Ser]8-CsA and Cs9 on mitochondria from different brain regions.
Mitochondrion
; 11(3): 421-9, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21167961
9.
Histone deacetylases control neurogenesis in embryonic brain by inhibition of BMP2/4 signaling.
PLoS One
; 3(7): e2668, 2008 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-18628975